CBE ID

3610

Title

30-day Risk Standardized Morbidity and Mortality Composite following Transcatheter Aortic Valve Replacement (TAVR)

Endorsement Status

Endorsed

Is Under Review

No

Next Maintenance Cycle

Spring 2027

Previous Endorsement Cycle

Spring 2021

Initial Endorsement

Tue, 11/30/2021 - 10:49

Steward

American College of Cardiology

1.0 New or Maintenance

Maintenance

1.1 Measure Structure

Composite Measure

1.3 Electronic Clinical Quality Measure (eCQM)

No

1.6 Measure Description

The TAVR 30-day morbidity/mortality composite is a hierarchical, multiple outcome risk model that estimates risk standardized results (reported as a “site difference”) for the purpose of benchmarking site performance. This measure estimates hospital risk standardized site difference for 5 endpoints (death from all causes, stroke, major or life-threatening bleeding, acute kidney injury, moderate or severe paravalvular aortic regurgitation) within 30 days following transcatheter aortic valve replacement. The measure uses clinical data available in the STS/ACC TVT Registry for risk adjustment for the purposes of benchmarking site to site performance on a rolling 3-year timeframe.

1.8 Level of Analysis

Facility

1.13 Data Dictionary

Not attached. I attest that all information will be provided where codes and/or value sets are needed (1.14a - 1.15c).

1.14 Numerator

A composite outcome including all-cause death, stroke, major or life threatening bleeding, acute kidney injury, moderate or severe paravalvular aortic regurgitation within 30 days following transcatheter aortic valve replacement (TAVR).If a patient experiences multiple outcomes captured in the overall rank composite measure, the outcome with the highest rank is assigned.

1.15 Denominator

Patients who had TAVR.

6.1.2 Current or Planned Use(s)

Public Reporting, Quality Improvement with Benchmarking (external benchmarking to multiple organizations)

6.1.3 Current Use(s)

Public Reporting, Quality Improvement with Benchmarking (external benchmarking to multiple organizations)

Exclusions

Hospitals are excluded if they do not meet eligibility criteria noted in S.7.
Patients are excluded if any of the following occur:
1) They did not have a first-time TAVR in the episode of care (admission),
2) The TAVR was subsequent to another procedure in the Registry (other TAVR, Mitral Leaflet Clip and/or TMVR) during that admission.
3) The patient is readmitted for a repeat TAVR (re-admission) and the initial TAVR was performed during the rolling 3-year timeframe for the measure.
4) They are in TVT Registry sponsored research studies (identified with research study=yes and research study device used during procedure).

Planned Use

Public Reporting

Risk Adjustment

Statistical risk model

The measure developer is different from the measure steward

No

Steward Organization

American College of Cardiology

Steward POC email

Jmayfield@acc.org